Impact of human papilloma virus HPV on immunosenescent CD57+ T-lymphocytes in cervical cancer patients

[1]  N. Sarmah,et al.  Immune Modulation in HLA-G Expressing Head and Neck Squamous Cell Carcinoma in Relation to Human Papilloma Virus Positivity: A Study From Northeast India , 2019, Front. Oncol..

[2]  E. Donadi,et al.  Variation sites at the HLA-G 3’ untranslated region confer differential susceptibility to HIV/HPV co-infection and aneuploidy in cervical cell , 2018, PloS one.

[3]  A. Lin,et al.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges , 2018, Front. Immunol..

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  S. Syrjänen.  Oral manifestations of human papillomavirus infections , 2018, European journal of oral sciences.

[6]  Ling Xu,et al.  T cell senescence and CAR-T cell exhaustion in hematological malignancies , 2018, Journal of Hematology & Oncology.

[7]  D. Calina,et al.  Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review) , 2018, International journal of oncology.

[8]  Iman H. Shehata,et al.  Human Leukocyte Antigen-G (HLA-G) Expression in Precancerous and Cancerous Cervical Lesions: Association with Human Papilloma Virus Infection and Host Immune Response. , 2018, The Egyptian journal of immunology.

[9]  J. Barrett,et al.  Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection , 2017, Viruses.

[10]  A. Olshan,et al.  Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer , 2016, Nature Genetics.

[11]  A. Lin,et al.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy , 2015, Molecular medicine.

[12]  Fan Yang,et al.  Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. , 2015, Cellular immunology.

[13]  M. Bonini,et al.  Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: a candidate molecule for therapeutic intervention and prognostic biomarker? , 2014, Biochimica et biophysica acta.

[14]  Xiaohua Li,et al.  Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis. , 2014, Immunology letters.

[15]  H. Putter,et al.  Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study , 2014, BMC Cancer.

[16]  J. Kirkwood,et al.  State of melanoma: an historic overview of a field in transition. , 2014, Hematology/oncology clinics of North America.

[17]  Seho Park,et al.  Human Leukocyte Antigen-G (HLA-G) Polymorphism and Expression in Breast Cancer Patients , 2014, PloS one.

[18]  M. Samson,et al.  Immunomodulatory Properties of HLA-G in Infectious Diseases , 2014, Journal of immunology research.

[19]  N. Rouas-Freiss,et al.  The Dual Role of HLA-G in Cancer , 2014, Journal of immunology research.

[20]  E. Donadi,et al.  HLA-G is differentially expressed in thyroid tissues. , 2014, Thyroid : official journal of the American Thyroid Association.

[21]  E. Lobos,et al.  HLA-G1 increases the radiosensitivity of human tumoral cells. , 2014, Cellular immunology.

[22]  P. Kuppen,et al.  Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients , 2013, British Journal of Cancer.

[23]  M. Schiffman,et al.  Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Guihua Chen,et al.  RNA interfering targeting human leukocyte antigen-G enhanced immune surveillance mediated by the natural killer cells on hepatocellular carcinoma. , 2013, Annals of clinical and laboratory science.

[25]  M. Bernaudin,et al.  Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. , 2013, The American journal of pathology.

[26]  A. Haholu,et al.  Immunoregulatory function of HLA-G in gastric cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[27]  A. Lin,et al.  Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. , 2012, Human immunology.

[28]  J. Shao,et al.  Expression of Human Leukocyte Antigen G is associated with Prognosis in Nasopharyngeal Carcinoma , 2012, International journal of biological sciences.

[29]  A. Poprach,et al.  HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma , 2012, Diagnostic Pathology.

[30]  G. Zografos,et al.  Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. , 2012, Anticancer research.

[31]  Y. Park,et al.  Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. , 2012, Tissue antigens.

[32]  Wenfu Zhou,et al.  Human leukocyte antigen‐G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma , 2011, International journal of cancer.

[33]  S. Yie,et al.  Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. , 2011, Tissue antigens.

[34]  S. Yie,et al.  Human Leukocyte Antigen-G (HLA-G) Expression in Cervical Lesions: Association With Cancer Progression, HPV 16/18 Infection, and Host Immune Response , 2010, Reproductive Sciences.

[35]  E. Donadi,et al.  Low Expression of Human Histocompatibility Soluble Leukocyte Antigen-G (HLA-G5) in Invasive Cervical Cancer With and Without Metastasis, Associated With Papilloma Virus (HPV) , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[36]  M. Schuler,et al.  Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. , 2010, Human immunology.

[37]  X. Zhang,et al.  Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma , 2009, Journal of cellular and molecular medicine.

[38]  Hong Yang,et al.  HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro , 2010, Annals of Surgical Oncology.

[39]  X. Zhang,et al.  Characterization of HLA-G expression in renal cell carcinoma. , 2009, Tissue antigens.

[40]  Sunghoon Kim,et al.  Correlation of Human Leukocyte Antigen-G (HLA-G) Expression and Disease Progression in Epithelial Ovarian Cancer , 2009, Reproductive Sciences.

[41]  Hong Yang,et al.  Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. , 2007, Lung cancer.

[42]  E. Jordanova,et al.  Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. , 2007, Gynecologic oncology.

[43]  B. Branger,et al.  Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. , 2006, Neoplasia.

[44]  E. Jordanova,et al.  Frequent HLA class I loss is an early event in cervical carcinogenesis. , 2005, Human immunology.

[45]  M. Campo,et al.  E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I , 2005, International journal of cancer.

[46]  Y. Allory,et al.  Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in , 2003, The American journal of pathology.

[47]  T. Tadakuma,et al.  Functional and Vβ repertoire characterization of human CD8+ T‐cell subsets with natural killer cell markers, CD56+ CD57− T cells, CD56+ CD57+ T cells and CD56− CD57+ T cells , 2003, Immunology.

[48]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[49]  B. Steinberg,et al.  Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. , 2001, Clinical immunology.

[50]  S. Ugurel,et al.  Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy , 2001 .

[51]  S. Seki,et al.  Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells , 2001, Immunology.

[52]  T Ishiji,et al.  Molecular Mechanism of Carcinogenesis by Human Papillomavirus‐16 , 2000, The Journal of dermatology.

[53]  J. Dausset,et al.  HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  月田光,et al.  Human Papilloma Virus , 1963, British medical journal.